NEW YORK, June 18- A U.S. appeals court on Thursday once again invalidated a patent held by Teva Pharmaceutical Industries Ltd on its top-selling multiple sclerosis drug Copaxone, clearing the way for the launch of a cheaper, generic version. The decision, by the U.S. Court of Appeals for the Federal Circuit, the nation's top patent tribunal, was a blow to Israel's...
*Q1 adjusted EPS $1.36 vs $1.25 forecast. *Raises 2015 adjusted EPS forecast to $5.05- $5.35. TEL AVIV, April 30- Teva Pharmaceutical Industries raised its 2015 earnings forecast after beating first-quarter estimates, and said it would devote "all necessary resources" to its $40 billion- plus bid for rival Mylan Inc..
*Q1 adjusted EPS $1.36 vs $1.25 forecast. *Raises 2015 adjusted EPS forecast to $5.05- $5.35. TEL AVIV, April 30- Teva Pharmaceutical Industries, which is seeking to acquire rival Mylan Inc for over $40 billion, raised its full-year earnings outlook after posting a bigger-than-expected increase in first-quarter profit.
The copied 20 mg version of the blockbuster drug, submitted by Sandoz, a unit of Swiss drugmaker Novartis AG, can be labeled "substitutable" for Copaxone, meaning that prescriptions for the brand-name drug can be automatically switched to the generic. The generic drug, called Glatopa, was developed collaboratively by Novartis and Momenta Pharmaceuticals Inc...
April 16- Momenta Pharmaceuticals Inc said the U.S. Food and Drug Administration approved the first generic version of Teva Pharmaceuticals Industries Ltd's top-selling multiple sclerosis drug, Copaxone. The agency cleared the application for the 20 mg version of the blockbuster drug, submitted by Momenta's partner Sandoz, a unit of Swiss drugmaker...
*Q4 adjusted EPS $1.31, in line with expectations. TEL AVIV, Feb 5- Teva Pharmaceutical Industries is ready to return to making acquisitions, it said on Thursday, after a year of focusing on costs under its new chief executive. The company posted fourth-quarter earnings of $1.31 per diluted share, excluding one-time items, against $1.42 a year earlier.
WASHINGTON, Jan 20- The U.S. Supreme Court on Tuesday ruled that Teva Pharmaceutical Industries Ltd can still benefit from patent protection for top-selling multiple sclerosis drug Copaxone, dealing a blow to generic drugmakers looking to market a cheaper rival product. In a 7-2 vote, the justices sent the case back to the U.S. Court of Appeals for the Federal...
Three small-cap drug firms are consistently the best biotech performers following the start of the American Society of Hematology's annual meeting.
Rock bottom interest rates will likely boost key stocks in the biotechnology sector, but Obamacare will dampen prospects for HMO shares.
TheStreet.com offers up 13 biotech predictions for 2013.
Take a look at some of Monday's midday movers:
Take a look at some of Monday morning's early movers:
When someone calls about a stock Cramer doesn't know, he does his homework and follows up.
The Lightning Round is extended in this CNBC.com exclusive feature.
So far this year, the Russell 2000 index of small-cap companies continues to outperform the Dow, and the S&P 500. While most of these companies average only a $1 billion dollar market capitalization, some of their returns are proving resilient to an economic slowdown.
Rising oil prices have not stopped consumers from going to the mall. Retailer Guess is enjoying a 15% surge in their stock price. The clothing company reported better than expected revenue.